lncRNA HAND2‑AS1 inhibits cancer cell proliferation, migration and invasion by downregulating ROCK1 in HPV‑positive and negative cervical squamous cell carcinoma

Jin,Liping; Ji,Jingquan; Shi,Linjie; Jin,Shuangling; Pei,Lihua

doi:10.3892/etm.2019.7830

lncRNA HAND2‑AS1 inhibits cancer cell proliferation, migration and invasion by downregulating ROCK1 in HPV‑positive and negative cervical squamous cell carcinoma

Authors:
- Liping Jin
- Jingquan Ji
- Linjie Shi
- Shuangling Jin
- Lihua Pei
View Affiliations

Affiliations: Department of Gynaecology and Obstetrics, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi 046000, P.R. China, Department of Pathophysiology, Changzhi Medical College, Changzhi, Shanxi 046000, P.R. China, Department of Urology, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi 046000, P.R. China
Published online on: July 30, 2019 https://doi.org/10.3892/etm.2019.7830
Pages: 2512-2518
Copyright: © Jin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Long non‑coding (lnc)RNA HAND2 antisense RNA 1 (HAND2‑AS1) exhibited tumor suppression activity in different types of cancer. However, its role in cervical squamous cell carcinoma (CSCC), which is frequently diagnosed among females, has not been elucidated. The current study revealed that lncRNA HAND2‑AS1 was downregulated, while Rho‑associated protein kinase 1 (ROCK1) was upregulated in serum of human papillomavirus (HPV)‑positive and ‑negative patients with CSCC compared with healthy controls. Correlation analysis revealed that the expression levels of lncRNA HAND2‑AS1 were negatively correlated with the expression levels of ROCK1 in HPV‑positive and ‑negative patients with CSCC but not in healthy controls. Downregulation of lncRNA HAND2‑AS1 distinguished patients with CSCC from healthy controls. Additionally, lncRNA HAND2‑AS1 overexpression led to reduced expression levels of ROCK1 in HPV‑positive and ‑negative human CSCC cell lines but not in normal cervical cell lines. ROCK1 overexpression did not significantly affect the expression of lncRNA HAND2‑AS1 in all the cell lines investigated. lncRNA HAND2‑AS1 overexpression inhibited, while ROCK1 overexpression promoted the proliferation, migration and invasion of HPV‑positive and ‑negative human CSCC cell lines but not normal cervical cell lines. ROCK1 overexpression attenuated the effects of lncRNA HAND2‑AS1 overexpression on cancer cell proliferation, migration and invasion. lncRNA HAND2‑AS1 may inhibit cancer cell proliferation, migration and invasion by downregulating ROCK1 in HPV‑positive and ‑negative CSCC.

View Figures

View References

1	DeSantis CE, Siegel RL, Sauer AG, Miller KD, Fedewa SA, Alcaraz KI and Jemal A: Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities. CA Cancer J Clin. 66:290–308. 2016. View Article : Google Scholar : PubMed/NCBI
2	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
3	Zheng R, Zeng H, Zhang S, Chen T and Chen W: National estimates of cancer prevalence in China, 2011. Cancer Lett. 370:33–38. 2016. View Article : Google Scholar : PubMed/NCBI
4	Waggoner SE: Cervical cancer. Lancet. 361:2217–2225. 2003. View Article : Google Scholar : PubMed/NCBI
5	Crosbie EJ, Einstein MH, Franceschi S and Kitchener HC: Human papillomavirus and cervical cancer. Lancet. 382:889–899. 2013. View Article : Google Scholar : PubMed/NCBI
6	Hildesheim A, Gonzalez P, Kreimer AR, Wacholder S, Schussler J, Rodriguez AC, Porras C, Schiffman M, Sidawy M, Schiller JT, et al: Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment. Am J Obstet Gynecol. 215:212.e1–212.e15. 2016. View Article : Google Scholar
7	Rodríguez-Carunchio L, Soveral I, Steenbergen RD, Torné A, Martinez S, Fusté P, Pahisa J, Marimon L, Ordi J and del Pino M: HPV-negative carcinoma of the uterine cervix: A distinct type of cervical cancer with poor prognosis. BJOG. 122:119–127. 2015. View Article : Google Scholar : PubMed/NCBI
8	Spizzo R, Almeida MI, Colombatti A and Calin GA: Long non-coding RNAs and cancer: A new frontier of translational research? Oncogene. 31:4577–4587. 2012. View Article : Google Scholar : PubMed/NCBI
9	Gutschner T and Diederichs S: The hallmarks of cancer: A long non-coding RNA point of view. RNA Biol. 9:703–719. 2012. View Article : Google Scholar : PubMed/NCBI
10	Qi P and Du X: The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mine. Mod Pathol. 26:155–165. 2013. View Article : Google Scholar : PubMed/NCBI
11	Kang Y, Zhu X, Xu Y, Tang Q, Huang Z, Zhao Z, Lu J, Song G, Xu H, Deng C and Wang J: Energy stress-induced lncRNA HAND2-AS1 represses HIF1α-mediated energy metabolism and inhibits osteosarcoma progression. Am J Cancer Res. 8:526–537. 2018.PubMed/NCBI
12	Yang X, Wang CC, Lee WYW, Trovik J, Chung TKH and Kwong J: Long non-coding RNA HAND2-AS1 inhibits invasion and metastasis in endometrioid endometrial carcinoma through inactivating neuromedin U. Cancer Lett. 413:23–34. 2018. View Article : Google Scholar : PubMed/NCBI
13	Wei L, Surma M, Shi S, Lambert-Cheatham N and Shi J: Novel insights into the roles of Rho kinase in cancer. Arch Immunol Ther Exp (Warsz). 64:259–278. 2016. View Article : Google Scholar : PubMed/NCBI
14	Kardani K, Agi E and Bolhassani A: Diagnosis of HPV Infections, HPV Testing in Patients. HPV Infections: Diagnosis, Prevention, and Treatment. Bolhassani: Bentham Science Publishers Ltd. (Sharjah). 129–158. 2018.
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Friedlander M and Grogan M; U.S. Preventative Services Task Force, : Guidelines for the treatment of recurrent and metastatic cervical cancer. Oncologist. 7:342–347. 2002.PubMed/NCBI
17	Symonds RP, Gourley C, Davidson S, Carty K, McCartney E, Rai D, Banerjee S, Jackson D, Lord R, McCormack M, et al: Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): A randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncol. 16:1515–1524. 2015. View Article : Google Scholar : PubMed/NCBI
18	Whatcott CJ, Ng S, Barrett MT, Hostetter G, Von Hoff DD and Han H: Inhibition of ROCK1 kinase modulates both tumor cells and stromal fibroblasts in pancreatic cancer. PLoS One. 12:e01838712017. View Article : Google Scholar : PubMed/NCBI
19	Chin VT, Nagrial AM, Chou A, Biankin AV, Gill AJ, Timpson P and Pajic M: Rho-associated kinase signalling and the cancer microenvironment: Novel biological implications and therapeutic opportunities. Expert Rev Mol Med. 17:e172015. View Article : Google Scholar : PubMed/NCBI
20	Cui M, Wang J, Li Q, Zhang J, Jia J and Zhan X: Long non-coding RNA HOXA11-AS functions as a competing endogenous RNA to regulate ROCK1 expression by sponging miR-124-3p in osteosarcoma. Biomed Pharmacother. 92:437–444. 2017. View Article : Google Scholar : PubMed/NCBI
21	Wang Y, Zeng X, Wang N, Zhao W, Zhang X, Teng S, Zhang Y and Lu Z: Long noncoding RNA DANCR, working as a competitive endogenous RNA, promotes ROCK1-mediated proliferation and metastasis via decoying of miR-335-5p and miR-1972 in osteosarcoma. Mol Cancer. 17:892018. View Article : Google Scholar : PubMed/NCBI